Members of the Fresenius Management Board purchased Fresenius shares with a total value of around €1.3 million over the past days as stipulated under the current compensation system. This underlines the commitment of the Management Board to drive the Company’s transformation at full speed. Fresenius is making strong progress in the Re-Vitalize phase of its journey towards #FutureFresenius. In 2024, which is expected to be a year of financial progression, the Company is focusing on deleveraging and pacing cost savings in order to build further earnings growth momentum and unlock value.

Members of the Fresenius Management Board purchased Fresenius shares with a total value of around €1.3 million over the past days as stipulated under the current compensation system. This underlines the commitment of the Management Board to drive the Company’s transformation at full speed. Fresenius is making strong progress in the Re-Vitalize phase of its journey towards #FutureFresenius. In 2024, which is expected to be a year of financial progression, the Company is focusing on deleveraging and pacing cost savings in order to build further earnings growth momentum and unlock value.

Fresenius Kabi and Formycon announced today that they have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara®* in Europe and Canada. The terms of the settlement are confidential. 

The agreement falls in line with Fresenius Kabi’s recent milestones in its Biopharma segment. The company has a track record of successful market entries in countries around the world. Fresenius Kabi’s consistently growing biosimilars portfolio is focused on oncology and immunology and set to bringing high-quality, affordable, and accessible treatment options to patients as well as healthcare providers in line with #FutureFresenius.

* Stelara® is a registered trademark of Johnson & Johnson
 

Fresenius Kabi and Formycon announced today that they have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara®* in Europe and Canada. The terms of the settlement are confidential. 

The agreement falls in line with Fresenius Kabi’s recent milestones in its Biopharma segment. The company has a track record of successful market entries in countries around the world. Fresenius Kabi’s consistently growing biosimilars portfolio is focused on oncology and immunology and set to bringing high-quality, affordable, and accessible treatment options to patients as well as healthcare providers in line with #FutureFresenius.

* Stelara® is a registered trademark of Johnson & Johnson
 

Contact

T +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Documents

Text as PDF document (PDF, 95 KB)

The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahead of time until 2027. Originally, it was set to run until 2025. The company thus ensures continuity on the Management Board in order to further advance the #FutureFresenius strategy.

Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius: “Sara Hennicken has successfully helped drive #FutureFresenius. In doing so, she has significantly improved the transparency in the finance function – this is an important prerequisite for managing the company and its businesses. We are very much looking forward to continuing our collaboration with her.”

Sara Hennicken (43) has been Chief Financial Officer of Fresenius since September 1, 2022. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to this, she worked in investment banking for 14 years, including nine years at Deutsche Bank. Most recently, Hennicken was Managing Director and Senior Client Executive in the Corporate Finance Coverage division. From 2005 to 2010, she worked for Citigroup in Frankfurt and London. Hennicken studied economics and business administration in Germany and the USA.

With its #FutureFresenius strategy, Fresenius is focusing on its operating companies Fresenius Kabi and Fresenius Helios. Both business segments occupy leading positions in attractive growth markets. With (Bio)Pharma, MedTech and Care Provision, they cover three central growth platforms in the therapy sector. To further increase the company's performance, the Management Board has also introduced a new, streamlined financial management system as a component of #FutureFresenius. Ambitious EBIT margin bands have been defined for the business segments as part of the Fresenius Financial Framework, which serve as benchmarks for management.